China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021

August 2016 | 90 pages | ID: CC89C217D70EN
DPI Research

Abstracts

The in–vitro diagnostics(IVD) market in China has been growing rapidly in the past few years and is expected to grow steadily in the next few years, with major growth potential in segments such as infectious disease testing, chronic disease testing and diagnosis in early stages of disease. Some of the major factors driving the growth of this market are the rising incidences of chronic lifestyle diseases, public health awareness, growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high–end products and an increase in the number of private hospitals and independent testing laboratories. However, low reimbursement rate, absence of quality products by the local companies, population factors and foreign companies faces difficulty to enter the low end IVD products market are restraining the growth of this market.

Long–term Outlook: The China In Vitro Diagnostics Market is expected to reach more than US$ 10 Billion by 2021 with strong double digit growth rate from 2016 to 2021.

China IVD Market: Segment wise Outlook

Immunoassay has emerged as a significant rapidly growing market segment in China IVD market. Immunoassay test controls nearly XX% market share by the year 2021. Other segments such as Clinical Chemistry, Molecular testing and POCT are poised to be remarkable expansion in the near future. Growing demand for infectious disease testing, chronic disease testing and diagnosis in early stages of disease will usher the China IVD market.

China IVD Market: Companies wise Outlook

Roche is the leading company with more than XX% market share in the China IVD market and is expected to hold its strong position in the market. Sysmex Corporation and Abbott Laboratories are the other top two players in the China IVD market. Mindray and Shanghai Kehua Bioengineering(KHB) are another major participant in this market with a good hold in clinical chemistry, immunoassay and molecular testing segments providing varieties of reagents nationwide and semi–auto and automatic biochemistry analyzers to low and mid–end market users.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market, market segments, company wise sales analysis, regulation, major distributors and laboratories of IVD and outlook of the Chinese IVD companies.

This report titled “China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021” has been analyzed from 10 viewpoints:

1. Market and Forecast (2010 – 2021)
2. Segment Wise Market and Forecast (2010 – 2021)
3. Company Wise IVD Sales and Forecast (2010 – 2021)
4. Regulation and its Latest Development
5. Future Prospects in Attractive In Vitro Diagnostics Segments
6. Regional Trends and Opportunities
7. Main Participants/Contributors
8. Major IVD Product Companies Outlook
9. Major Private Clinical Labs and Diagnostic Services Companies Outlook
10. Market Growth Drivers and Challenges

The following segments of the China In Vitro Diagnostics market are detailed with size and six year forecast.

• Clinical Chemistry
• Immunoassay
• Molecular Testing
• Self–Monitoring of Blood Glucose (SMBG)
• Point of Care Testing (POCT)
• Hematology
• Coagulation
• Microbiology

The following companies of the China In Vitro Diagnostics market are detailed with size and six year forecast

• Roche Diagnostics
• Abbott Laboratories
• Mindray Medical International Limited
• Sysmex Corporation
• Shanghai Kehua Bio–Engineering Co. Ltd.
• Other Companies

The following Chinese companies of the China In Vitro Diagnostics market are detailed with company overview and its product portfolio

• Mindray Medical International Limited
• Shanghai Fosun Pharmaceutical Group
• Mingyuan Medicare
• Da An Gene Co. Ltd.
• Shanghai Kehua Bio–Engineering Co. Ltd.
• Zhejiang D.a. Diagnostics Technology Co., Ltd
• ADICON Clinical Laboratories
• Guangzhou Kingmed Diagnostics Center Co. Ltd.
• Kindstar Global
• BGI – Shenzhen
• OriGene Technologies

Contents

1. EXECUTIVE SUMMARY

2. CHINA IN VITRO DIAGNOSTICS MARKET & FORECAST (2010 – 2021)

3. CHINA IN VITRO DIAGNOSTICS MARKET SHARE & FORECAST (2010 – 2021)

3.1 China In Vitro Diagnostics Market Share Outlook
3.2 China In Vitro Diagnostics Companies Share Outlook

4. CHINA IN VITRO DIAGNOSTICS MARKET – SEGMENT ANALYSIS (2010 – 2021)

4.1 China Clinical Chemistry Market & Forecast
4.2 China Immunoassay Market & Forecast
4.3 China Molecular Testing Market & Forecast
4.4 China Self–Monitoring of Blood Glucose (SMBG) Market & Forecast
4.5 China Point of Care Testing (POCT) Market & Forecast
4.6 China Hematology Market & Forecast
4.7 China Coagulation Market & Forecast
4.8 China Microbiology Market & Forecast

5. CHINA IN VITRO DIAGNOSTICS MARKET – COMPANY WISE SALES ANALYSIS (2010 – 2021)

5.1 Roche Diagnostics – China IVD Sales & Forecast
5.2 Abbott Laboratories – China IVD Sales & Forecast
5.3 Mindray Medical International Limited – China IVD Sales & Forecast
5.4 Sysmex Corporation – China IVD Sales & Forecast
5.5 Shanghai Kehua Bio–Engineering Co. Ltd. – China IVD Sales & Forecast
5.6 Other Companies – China IVD Sales & Forecast

6. CHINA IVD – REGULATION & ITS LATEST DEVELOPMENT

7. CHINA IVD – FUTURE PROSPECTS IN ATTRACTIVE IN VITRO DIAGNOSTICS SEGMENTS

8. CHINA IVD – REGIONAL TRENDS & OPPORTUNITIES

9. CHINA IVD – MAIN PARTICIPANTS/CONTRIBUTORS

9.1 China IVD Market – Main Distributors
9.2 China IVD Market – Major Laboratories
9.3 China IVD Market – Major Foreign & Regional Companies

10. CHINA – MAJOR IVD PRODUCT COMPANIES OUTLOOK

10.1 Mindray Medical International Limited
10.2 Shanghai Fosun Pharmaceutical Group
10.3 Mingyuan Medicare
10.4 Da An Gene Co. Ltd
10.5 Shanghai Kehua Bio–Engineering Co. Ltd

11. CHINA – MAJOR PRIVATE CLINICAL LABS & DIAGNOSTIC SERVICES COMPANIES OUTLOOK

11.1 Zhejiang D.a. Diagnostics Technology Co., Ltd
11.2 ADICON Clinical Laboratories (Privately held)
11.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
11.4 Kindstar Global
11.5 BGI – Shenzhen
11.6 OriGene Technologies

12. CHINA IN VITRO DIAGNOSTICS MARKET – GROWTH DRIVERS

12.1 China Healthcare Reforms – A Progress to Date & Next Steps
12.2 Upgradation of Automated Testing Levels & Investment by Government in Hospitals Will Drive the China IVD Industry
12.3 Public Health Awareness & Increased Incidence of Hypertension, Cardio Cerebrovascular Illness, Diabetes, Arthritis & Cancer
12.4 Increasing Number of Private Hospitals & Independent Testing Laboratories Boost the Demand of IVD Testing in China

13. CHINA IN VITRO DIAGNOSTICS MARKET – CHALLENGES

13.1 Value Added Markets of New Products & Household Consumption Markets
13.2 Low Reimbursement Rate of the Basic Medical Care Insurance for Clinical Tests Will Discourage the People from IVD Tests.
13.3 Absence of Quality Products By the Local Companies Hindrance the Growth of IVD Market in China
13.4 Population Factors
13.5 Foreign Companies Faces Difficulty to Enter the Low End IVD Products Market in China
13.6 Reimbursement Rates Differ in Many Parts of China Which Creates Problems To Popularizing the IVD Products

List Of Tables

LIST OF TABLES:

Table 3–1: China – In Vitro Diagnostics Market Share(Percent),2010 – 2015
Table 3–2: China – In Vitro Diagnostics Market Share(Percent),2016 – 2021

List Of Figures

LIST OF FIGURES:

Figure 2–1: China – IVD Market (Million US$), 2010 – 2015
Figure 2–2: China – Forecast for IVD Market (Million US$), 2016 – 2021
Figure 3–1: China – In Vitro Diagnostics Companies Share(Percent), 2015
Figure 4–1: China – Clinical Chemistry Market (Million US$), 2010 – 2015
Figure 4–2: China – Forecast for Clinical Chemistry Market (Million US$), 2016 – 2021
Figure 4–3: China – Immunoassay Market (Million US$), 2010 – 2015
Figure 4–4: China – Forecast for Immunoassay Market (Million US$), 2016 – 2021
Figure 4–5: China – Molecular Testing Market (Million US$), 2010 – 2015
Figure 4–6: China – Forecast for Molecular Testing Market (Million US$), 2016 – 2021
Figure 4–7: China – SMBG Market (Million US$), 2010 – 2015
Figure 4–8: China – Forecast for SMBG Market (Million US$), 2016 – 2021
Figure 4–9: China – POCT Market (Million US$), 2010 – 2015
Figure 4–10: China – Forecast for POCT Market (Million US$), 2016 – 2021
Figure 4–11: China – Hematology Market (Million US$), 2010 – 2015
Figure 4–12: China – Forecast for Hematology Market (Million US$), 2016 – 2021
Figure 4–13: China – Coagulation Market (Million US$), 2010 – 2015
Figure 4–14: China – Forecast for Coagulation Market (Million US$), 2016 – 2021
Figure 4–15: China – Microbiology Market (Million US$), 2010 – 2015
Figure 4–16: China – Forecast for Microbiology Market (Million US$), 2016 – 2021
Figure 5–1: Roche Diagnostics – China IVD Sales (Million US$), 2010 – 2015
Figure 5–2: Roche Diagnostics – Forecast for China IVD Sales (Million US$), 2016 – 2021
Figure 5–3: Abbott Laboratories – China IVD Sales (Million US$),2012 – 2015
Figure 5–4: Abbott Laboratories – Forecast for China IVD Sales (Million US$),2016 – 2021
Figure 5–5: Mindray Medical International Limited – China IVD Sales (Million US$),2010 – 2015
Figure 5–6: Mindray Medical International Limited – Forecast for China IVD Sales (Million US$),2016 – 2021
Figure 5–7: Sysmex Corporation – China IVD Sales (Million US$),2010 – 2015
Figure 5–8: Sysmex Corporation – Forecast for China IVD Sales (Million US$),2016 – 2021
Figure 5–9: Shanghai Kehua Bio–Engineering Co. Ltd. – China IVD Sales (Million US$),2011 – 2015
Figure 5–10: Shanghai Kehua Bio–Engineering Co. Ltd. – China IVD Sales (Million US$),2016 – 2021
Figure 9–1: Kindstar – Collaboration with hospitals in China (Number), 2006 – 2012